PP
LPCN icon

Paloma Partners’s Lipocine LPCN Stock Holding History

Paloma Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,694
Closed -$184K – 2288
2017
Q2 		$184K Buy
+2,694
New +$176K ﹤0.01% 2017

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Paloma Partners's LPCN Position: Q3 2017 in Review

Paloma Partners sold out of Lipocine (LPCN) in Q3 2017, closing a stake of 2,694 shares — an estimated $184K sold.

Paloma Partners first reported a position in LPCN in Q2 2017 and held it in 1 quarter. The position peaked at $184K in Q2 2017. 37 funds tracked by Wall St. Rank hold LPCN as of Q3 2017.

  • Paloma Partners reported no remaining Lipocine position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 2,694 Lipocine shares in Q3 2017, an estimated $184K.
  • Paloma Partners first reported a position in Lipocine in Q2 2017 and held it in 1 quarter.
  • Paloma Partners's Lipocine position peaked at $184K in Q2 2017.
  • 37 funds tracked by Wall St. Rank held Lipocine as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.